» Articles » PMID: 29056913

Anti-Alzheimer's Studies on β-Sitosterol Isolated from L

Overview
Journal Front Pharmacol
Date 2017 Oct 24
PMID 29056913
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

The family Polygonaceae is known for its traditional use in the management of various neurological disorders including Alzheimer's disease (AD). In search of new anti-AD drugs, β-sitosterol isolated from was subjected to , behavioral and molecular docking studies to confirm its possibility as a potential anti-Alzheimer's agent. The AChE, BChE inhibitory potentials of β-sitosterol were investigated following Ellman's assay. The antioxidant activity was tested using DPPH, ABTS and HO assays. Behavioral studies were performed on a sub-strain of transgenic mice using shallow water maze (SWM), Y-maze and balance beam tests. β-sitosterol was tested for inhibitory potentials against cholinesterase's and free radicals in the frontal cortex (FC) and hippocampus (HC). The molecular docking study was performed to predict the binding mode of β-sitosterol in the active sites of AChE and BChE as inhibitor. Considerable and cholinesterase inhibitory effects were observed in the β-sitosterol treated groups. β-sitosterol exhibited an IC value of 55 and 50 μg/ml against AChE and BChE respectively. Whereas, the activity of these enzymes were significantly low in FC and HC homogenates of transgenic animals. Molecular docking studies also support the binding of β-sitosterol with the target enzyme and further support the and results. In the antioxidant assays, the IC values were observed as 140, 120, and 280 μg/ml in the DPPH, ABTS and HO assays respectively. The free radicals load in the brain tissues was significantly declined in the β-sitosterol treated animals as compared to the transgenic-saline treated groups. In the memory assessment and coordination tasks including SWM, Y-maze and balance beam tests, β-sitosterol treated transgenic animals showed gradual improvement in working memory, spontaneous alternation behavior and motor coordination. These results conclude that β-sitosterol is a potential compound for the management of memory deficit disorders like AD.

Citing Articles

Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review.

ALNasser M, Alboraiy G, Alsowig E, Alqattan F Brain Sci. 2025; 15(2).

PMID: 40002547 PMC: 11852592. DOI: 10.3390/brainsci15020215.


Appraisal of the Neuroprotective Potentials of Isoeugenol Using and Approaches.

Alyami B, Ahmad Z, Ghufran M, Mahnashi M, Sadiq A, Ayaz M Curr Neuropharmacol. 2025; 23(3):317-328.

PMID: 39989009 PMC: 11808583. DOI: 10.2174/1570159X22666240329125626.


Exploring the potential mechanism of Polygonatum sibiricum for Alzheimer's disease based on network pharmacology and molecular docking: An observational study.

Luo L, Pan Y, Chen F, Zhang Z Medicine (Baltimore). 2025; 103(52):e40726.

PMID: 39969345 PMC: 11688029. DOI: 10.1097/MD.0000000000040726.


Textural, Color, and Sensory Analysis of Cookies Prepared with Hemp Oil-Based Oleogels.

Leahu A, Ghinea C, Ropciuc S, Damian C Gels. 2025; 11(1.

PMID: 39852016 PMC: 11764874. DOI: 10.3390/gels11010046.


Dietary supplements for prevention of Alzheimer's disease: and molecular docking studies.

Mohamed D, Mohamed R, Fouda K, Mabrok H Iran J Basic Med Sci. 2025; 28(2):170-180.

PMID: 39850118 PMC: 11756737. DOI: 10.22038/ijbms.2024.79960.17320.


References
1.
Minati L, Edginton T, Bruzzone M, Giaccone G . Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen. 2009; 24(2):95-121. PMC: 10846154. DOI: 10.1177/1533317508328602. View

2.
Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M . Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010; 9(7):702-16. DOI: 10.1016/S1474-4422(10)70119-8. View

3.
Lees A, Mok H, Lees R, McCluskey M, Grundy S . Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. Atherosclerosis. 1977; 28(3):325-38. DOI: 10.1016/0021-9150(77)90180-0. View

4.
Birks J . Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006; (1):CD005593. PMC: 9006343. DOI: 10.1002/14651858.CD005593. View

5.
Katalinic M, Rusak G, Domacinovic Barovic J, Sinko G, Jelic D, Antolovic R . Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur J Med Chem. 2009; 45(1):186-92. DOI: 10.1016/j.ejmech.2009.09.041. View